6.2.3. prophylactic pelvic lymph node dissection. prophylactic plnd (pplnd) cases represents staging procedure thus identify candidates early adjuvant therapy, although select patients may also provide therapeutic benefit. 6.2.3.1. indications prophylactic pelvic lymph node dissection 6.2.3.1.1. risk factors pelvic nodal metastasis identify patients pelvic ln metastasis absence radiological evidence ln involvement, several studies tried develop generalized estimating models based inguinal characteristics using logistic regression multivariate analysis. among various predictors, number positive inguinal lns (1–2 vs. 3, more, extra-capsular extension) associated positive pelvic lns 0–6.5% patients vs. 33–67% patients . presence extracapsular spread also consistently significantly associated positive ipsilateral pelvic ln metastasis 4 studies [249-252] strong immunoreactivity p53, ln density > 30% primary tumour grade also reported predictors pelvic ln involvement . 6.2.3.2. acceptable dissection? study yao et el., authors prospectively mapped distribution positive pelvic lns time plnd 128 patients . patients underwent bilateral plnd (86.7%). median number nodes retrieved per groin 18 (interquartile range [iqr] 10–30), distribution positive nodes external iliac, obturator, common iliac, internal iliac presacral packages 50%, 36.6%, 7%, 6.4% 0%, respectively. notably two patients observed crossover metastasis one inguinal region contralateral pelvic region, defying accepted understanding historical literature. extent dissection considered context overall- rfs statistically significant difference . similar data seen study zhu et al., external iliac package commonly involved obturator common iliac packages . evaluate prognostic impact ln yield survival outcomes penile scc, chipollini et al., examined 198 patients undergoing plnd . cohort found ln yield > 9 predictor rfs (hr: 0.53, p = 0.032). 6.2.3.3. survival recurrence evidence pplnd additional therapeutic effect surveillance adjuvant radiotherapy (see section 6.4.2.2) limited significant controversy remains. djajadiningrat et al., estimated 5-year dss patients treated pplnd 51%. patients positive pelvic nodes significantly worse 5-year dss without pelvic involvement (17%, 95% ci: 6–47 vs. 62%, 95% ci: 50–76, p < 0.001) . retrospective multicentre study compared outcomes bilateral pplnd n2 n3 disease vs. surgery reported better 5-year os pplnd group (35% vs. 25%) without reaching statistical significance . n2 patients, 3-year os significantly better plnd group compared no-surgery group (83.3% vs. 50.2%, p = 0.03) . difference evident n3 patients. 6.2.3.4. complications limited data available regarding reporting complications plnd. complicated fact patients already undergone rilnd carries significant morbidity discussed above. single-centre experience 89 patients, undergoing open plnd penile cancer reported overall complication rate 18%. nine patients wound complications including infection, seroma, dehiscence. remaining 5 patients non-wound-related complications pneumonia, delirium, ileus . 6.2.3.5. minimally-invasive versus open pelvic lymph node dissection sr commissioned panel reported studies examined role minimally-invasive pplnd setting penile cancer plnd. is, however, significant body evidence exists common urological malignancies demonstrates equivalent oncological outcome well improved morbidity profile recovery profile. 6.2.3.6. summary evidence guidelines prophylactic pelvic lymph node dissection summary evidenceleprophylactic plnd cases represents staging procedure thus identify candidates early adjuvant therapy, although select patients may also provide therapeutic benefit.3three positive inguinal nodes extranodal extension cancer inguinal nodes associated significantly higher incidence pelvic ln metastases.3 recommendationsstrength ratingoffer open minimally-invasive prophylactic ipsilateral pelvic lymphadenectomy topatients if:three inguinal nodes involved one side pathological examinationextranodal extension reported pathological examinationweakcomplete surgical inguinal pelvic nodal management within three months diagnosis (unless patient undergone neoadjuvant chemotherapy).weak